TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05258279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion Q3W
Study: NCT06545097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Once daily on Day 2 (with Cebranopadol 400 ug)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 2 days
Study: NCT04996758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab and Anlotinib
Description: Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
Study: NCT06047626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Reduction Diet
Description: Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Health Curriculum
Description: These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
Study: NCT05050136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched to study drug without the active pharmaceutical ingredient
Study: NCT06459388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilizing Reversals and Rhythmic Stabilization
Description: 3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Proprioceptive Neuromuscular Facilitation
Description: The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
Study: NCT05258110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study: NCT05875948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2R01
Description: Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2R01
Description: Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R2R01
Description: Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.
Study: NCT05746845

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)
Study: NCT05956119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling + physiotherapy (standard/usual care)
Description: same that arm descrption

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham dry needling + physiotherapy (standard/usual care)
Description: same that arm description
Study: NCT06030674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand cannabis emissions/smoke exposure
Description: This is an environmental exposure performed in public places where people are consuming cannabis.
Study: NCT06646185

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Pads
Description: Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Cups
Description: Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
Study: NCT05832138

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ONLOOP program
Description: Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONLOOP program
Description: Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
Study: NCT06021301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin and Microneedling
Description: First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
Study: NCT05934513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH009
Description: patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
Study: NCT06533943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
Study: NCT05476939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation.
Study: NCT05356806

Intervention type: OTHER
Intervention: Supportive periodontal and periimplant care
Description: Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space
Study: NCT04989946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: DNA vaccine encoding androgen receptor ligand-binding domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: DNA vaccine encoding androgen receptor ligand-binding domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: DNA vaccine encoding androgen receptor ligand-binding domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: DNA vaccine encoding androgen receptor ligand-binding domain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLT PET/CT
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
Study: NCT06052410

Intervention type: OTHER
Group type: OTHER
Intervention: Early Intervention
Description: Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.

Intervention type: OTHER
Group type: OTHER
Intervention: Home Programme
Description: For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
Study: NCT04994457

Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses

Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses

Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses

Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses

Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses

Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Automated Perimetry
Description: Standard of care perimeter

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Automated Perimetry
Description: Standard of care perimeter

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Automated Perimetry
Description: Standard of care perimeter
Study: NCT05366777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen/ibuprofen fixed-dose combination
Description: Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml of normal saline
Study: NCT06200766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate as a nasal spray
Description: Subjects received 2 presses in each side nostrils at the same time point (± 1h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate as a nasal spray
Description: Subjects received 2 presses in each side nostrils at the same time point (± 1h).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate as a nasal spray
Description: Subjects received 2 presses in each side nostrils at the same time point (± 1h).
Study: NCT06078904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Colchicine 0.5 MG, one pill a day, oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.375 MG
Description: Colchicine 0.375 MG, one pill a day, oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.25 MG
Description: Colchicine 0.25 MG, one pill a day, oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one pill a day, oral intake
Study: NCT06059495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)
Study: NCT05844813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin+Ifosfamide+Anlotinib(AI+A)
Description: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Surgery
Description: Radical sarcoma resectional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Surgery
Description: Radical sarcoma resectional surgery
Study: NCT06303739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: 25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psilocybin
Description: 25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
Study: NCT05330065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and camrelizumab
Description: Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days.
Study: NCT04866797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclic merocyanine
Description: long-UVA absorber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo